Company Description
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases.
The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Aug 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Gerald T. Proehl |
Contact Details
Address: 3525 Del Mar Heights Rd., #322 San Diego, California 92130 United States | |
| Phone | (858)-223-0882 |
| Website | dermatarx.com |
Stock Details
| Ticker Symbol | DRMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001853816 |
| CUSIP Number | 249845108 |
| ISIN Number | US2498453065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald T. Proehl | Founder, President, Chief Executive Officer and Chairman |
| David F. Hale | Co-Founder and Lead Independent Director |
| Kyri K. Van Hoose CPA, M.B.A. | Senior Vice President and Chief Financial Officer |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President and Chief Development Officer |
| Sean Proehl | Senior Director of Legal and Business Development |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2024 | ARS | Filing |
| Mar 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 4, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 12, 2024 | 8-K | Current Report |
| Dec 15, 2023 | EFFECT | Notice of Effectiveness |
| Dec 15, 2023 | 424B3 | Prospectus |